Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
